Scrip's Rough Guide to Immuno-Oncology
This article was originally published in Scrip
If there's one area of pharmaceutical R&D guaranteed to stay in the spotlight over the next few years it's immuno-oncology – this is one of the most promising and quickest-growing areas of cancer research, as well as one of the most active areas for licensing deals and acquisitions.
You may also be interested in...
Doesn't every biopharma company have an immuno-oncology strategy these days? It certainly seems that way, considering the number of drug developers that are labeling their therapeutic candidates as immunotherapies regardless of whether the description truly fits their asset.
Forte Biosciences’ attempts to use a new approach to treating inflammatory skin disease using a topical live biotherapeutic, FB-401, have come to a crashing halt at Phase II. Where the company goes next remains to be seen.
In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are five new hematology products that could make their market debuts (or return) next year.